Allergy Therapeutics plc (LON:AGY - Get Free Report) shares crossed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of GBX 4.59 ($0.06) and traded as low as GBX 4.50 ($0.06). Allergy Therapeutics shares last traded at GBX 5.42 ($0.07), with a volume of 493,909 shares.
Allergy Therapeutics Price Performance
The company's 50-day moving average is GBX 4.78 and its two-hundred day moving average is GBX 4.61. The company has a debt-to-equity ratio of 37.22, a current ratio of 1.40 and a quick ratio of 1.48. The firm has a market cap of £262.35 million, a P/E ratio of -91.67, a PEG ratio of -30.70 and a beta of 1.40.
About Allergy Therapeutics
(
Get Free Report)
Allergy Therapeutics plc, a commercial biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics.
Recommended Stories
Before you consider Allergy Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Allergy Therapeutics wasn't on the list.
While Allergy Therapeutics currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
